Clinically significant cardiac disease in patients with Hodgkin lymphoma treated with mediastinal irradiation.

This study assessed the cumulative incidence of clinically significant cardiac disease in 1279 Hodgkin lymphoma patients treated with mediastinal irradiation and quantified the standard incidence ratios (SIRs) and absolute excess risks of cardiac procedures compared with a normal matched population. Cox regression analysis was used to explore factors associated with cardiac complications. Poisson regression analysis of SIRs was used to estimate the excess risk of cardiac interventions from mediastinal irradiation. After a median follow-up of 14.7 years, 187 patients experienced 636 cardiac events and 89 patients required a cardiac procedure. 5-, 10-, 15-, and 20-year cumulative incidence rates of cardiac events were 2.2%, 4.5%, 9.6%, and 16%. SIRs for cardiac procedures were increased for coronary artery bypass graft (3.19), percutaneous intervention (1.55), implantable cardioverter defibrillator or pacemaker placement (1.9), valve surgery (9.19), and pericardial surgery (12.91). Absolute excess risks were 18.2, 19.3, 9.4, 14.1, and 4.7 per 10 000 person-years, respectively. Older age at diagnosis and male sex were predictors for cardiac events. However, younger age at diagnosis was associated with excess risk specifically from radiation therapy compared with the general population. These results may help guideline development for both the types and timing of cardiac surveillance in survivors of Hodgkin lymphoma.

[1]  J. Lubin,et al.  Coronary artery disease mortality in patients treated for hodgkin's disease , 2010, Cancer.

[2]  R. Tsang,et al.  Cardiac morbidity following modern treatment for Hodgkin lymphoma: Supra-additive cardiotoxicity of doxorubicin and radiation therapy , 2008, Leukemia & lymphoma.

[3]  A. Hart,et al.  Late cardiotoxicity after treatment for Hodgkin lymphoma. , 2007, Blood.

[4]  A. Horwich,et al.  Myocardial infarction mortality risk after treatment for Hodgkin disease: a collaborative British cohort study. , 2007, Journal of the National Cancer Institute.

[5]  R. De Angelis,et al.  Hodgkin disease survival in Europe and the U.S. , 2006, Cancer.

[6]  A. Avilés,et al.  Late cardiac toxicity secondary to treatment in Hodgkin's disease. A study comparing doxorubicin, epirubicin and mitoxantrone in combined therapy , 2005, Leukemia & lymphoma.

[7]  S. Lipsitz,et al.  Cardiovascular status in long-term survivors of Hodgkin's disease treated with chest radiotherapy. , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[8]  V. Coviello,et al.  Cumulative Incidence Estimation in the Presence of Competing Risks , 2004 .

[9]  C. Pepine,et al.  Valvular dysfunction and carotid, subclavian, and coronary artery disease in survivors of hodgkin lymphoma treated with radiation therapy. , 2003, JAMA.

[10]  H. Bartelink,et al.  Long-term cause-specific mortality of patients treated for Hodgkin's disease. , 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[11]  S. Hancock,et al.  Asymptomatic cardiac disease following mediastinal irradiation. , 2003, Journal of the American College of Cardiology.

[12]  J. Friedberg,et al.  Long-term survival and competing causes of death in patients with early-stage Hodgkin's disease treated at age 50 or younger. , 2002, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[13]  P. Simpson,et al.  Statistical methods in cancer research , 2001, Journal of surgical oncology.

[14]  J Crowley,et al.  Estimation of failure probabilities in the presence of competing risks: new representations of old estimators. , 1999, Statistics in medicine.

[15]  L. Steinherz Correction: Pregnancy-Related Thromboembolism , 1997, Annals of Internal Medicine.

[16]  H. Klein Anthracycline-Induced Cardiotoxicity , 1997, Annals of Internal Medicine.

[17]  J. Kongerud,et al.  Increased risk of heart valve regurgitation after mediastinal radiation for Hodgkin's disease: an echocardiographic study. , 1996, Heart.

[18]  L. Kalish,et al.  Long-term survival in Hodgkin's disease relative impact of mortality, second tumors, infection, and cardiovascular disease. , 1995, The cancer journal from Scientific American.

[19]  S L Hancock,et al.  Factors affecting late mortality from heart disease after treatment of Hodgkin's disease. , 1993, JAMA.

[20]  E. Thiel,et al.  Evaluation of late cardiotoxicity with pulsed Doppler echocardiography in patients treated for Hodgkin's disease , 1993, British journal of haematology.

[21]  S. Hancock,et al.  Cardiac disease following treatment of Hodgkin's disease in children and adolescents. , 1993, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[22]  Norman E. Breslow,et al.  Statistical Methods in Cancer Research, Vol. II: The Design and Analysis of Cohort Studies. , 1990 .

[23]  E. Noordijk,et al.  Causes of death after therapy for early stage Hodgkin's disease entered on EORTC protocols. EORTC Lymphoma Cooperative Group. , 1990, International journal of radiation oncology, biology, physics.

[24]  T. Landberg,et al.  Original article: Late cardiac effects after mantle radiotherapy in patients with Hodgkin's disease , 1990 .

[25]  P. Siltanen,et al.  Late cardiac effects of mediastinal radiotherapy in patients with Hodgkin's disease , 1987, Cancer.

[26]  J. D. Herman,et al.  Echocardiographic abnormalities following cardiac radiation. , 1985, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[27]  R. Papac Chemotherapy plus involved-field radiation in early-stage Hodgkin's disease. , 2008, The New England journal of medicine.

[28]  P. Voûte,et al.  Anthracycline-induced clinical heart failure in a cohort of 607 children: long-term follow-up study. , 2001, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[29]  P. Kaufmann,et al.  Cardiac risk after mediastinal irradiation for Hodgkin's disease. , 1998, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.

[30]  R. Hoppe Hodgkin's disease: complications of therapy and excess mortality. , 1997, Annals of oncology : official journal of the European Society for Medical Oncology.

[31]  R. Jenni,et al.  Cardiac lesions after mediastinal irradiation for Hodgkin's disease. , 1994, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.

[32]  D. Linch,et al.  Late mortality in young BNLI patients cured of Hodgkin's disease. , 1994, Annals of oncology : official journal of the European Society for Medical Oncology.

[33]  R. Gelber,et al.  Timing of baseline quality of life assessment in an international adjuvant breast cancer trial: its effect on patient self-estimation. The International Breast Cancer Study Group. , 1994, Annals of oncology : official journal of the European Society for Medical Oncology.

[34]  T. Landberg,et al.  Late cardiac effects after mantle radiotherapy in patients with Hodgkin's disease. , 1990, Annals of oncology : official journal of the European Society for Medical Oncology.

[35]  Norman E. Breslow,et al.  The design and analysis of cohort studies , 1987 .

[36]  N. Breslow,et al.  Statistical methods in cancer research. Volume II--The design and analysis of cohort studies. , 1987, IARC scientific publications.